Skip to main content
USNA
NYSE Life Sciences

USANA Reports 74% Drop in Net Earnings, 72% Effective Tax Rate, and Goodwill Impairment Amid Core Business Decline

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$17.72
Mkt Cap
$323.937M
52W Low
$16.715
52W High
$38.32
Market data snapshot near publication time

summarizeSummary

USANA Health Sciences reported a 74.4% decrease in net earnings and a significant rise in its effective tax rate for 2025, alongside a goodwill impairment and a decline in core active customers.


check_boxKey Events

  • Net Earnings Plummet 74.4%

    Net earnings attributable to USANA decreased by 74.4% to $10.8 million in 2025, down from $42.03 million in 2024, significantly impacting profitability.

  • Diluted EPS Falls Sharply

    Diluted earnings per share dropped to $0.58 in 2025, a substantial decrease from $2.19 in the previous year.

  • Effective Tax Rate Soars to 72.4%

    The effective tax rate dramatically increased to 72.4% in 2025, up from 44.9% in 2024, largely due to lower U.S. earnings before taxes and relatively similar foreign taxes.

  • Goodwill Impairment and Cost Realignment Charges

    The company recognized a $6.527 million non-cash goodwill impairment charge and a $6.463 million one-time cost realignment charge, primarily for employee severance, reflecting operational difficulties.


auto_awesomeAnalysis

USANA Health Sciences reported a significant decline in its 2025 financial performance, with net earnings attributable to the company plummeting by 74.4% to $10.8 million and diluted EPS falling to $0.58 from $2.19 in the prior year. This sharp drop was primarily driven by a lower operating margin and a substantial increase in the effective tax rate to 72.4% from 44.9%. The company also recorded a $6.527 million goodwill impairment charge and a $6.463 million cost realignment charge, including employee severance, indicating operational challenges. Furthermore, the core nutritional business experienced a notable 14.8% decrease in active customers, signaling fundamental issues despite the Hiya acquisition contributing $130.0 million in sales.

At the time of this filing, USNA was trading at $17.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $323.9M. The 52-week trading range was $16.72 to $38.32. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed USNA - Latest Insights

USNA
Apr 07, 2026, 4:50 PM EDT
Filing Type: DEF 14A
Importance Score:
7
USNA
Mar 16, 2026, 2:57 PM EDT
Filing Type: 10-K
Importance Score:
9
USNA
Feb 17, 2026, 8:33 PM EST
Filing Type: 8-K
Importance Score:
8
USNA
Feb 11, 2026, 4:51 PM EST
Filing Type: 8-K/A
Importance Score:
8
USNA
Jan 12, 2026, 6:29 AM EST
Filing Type: 8-K
Importance Score:
7
USNA
Jan 08, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
7